Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 5

Effectiveness of twice daily azelastine nasal spray in patients with seasonal allergic rhinitis

Authors Horak F

Published 10 October 2008 Volume 2008:4(5) Pages 1009—1022

DOI https://doi.org/10.2147/TCRM.S3229

Review by Single-blind

Peer reviewer comments 2

Friedrich Horak

Medical University Vienna, ENT – Univ. Clinic, Vienna, Austria

Abstract: Azelastine nasal spray (Allergodil®, Lastin®, Afluon®; Meda AB, Stockholm, Sweden) is a fast-acting, efficacious and well-tolerated H1-receptor antagonist for the treatment of rhinitis. In addition it also has mast-cell stabilizing and anti-inflammatory properties, reducing the concentration of leukotrienes, kinins and platelet activating factor in vitro and in vivo, as well as inflammatory cell migration in rhinitis patients. Well-controlled studies in patients with seasonal allergic rhinitis (SAR), perennial rhinitis (PR) or vasomotor rhinitis (VMR) confirm that azelastine nasal spray has a rapid onset of action, and improves nasal symptoms associated with rhinitis such as nasal congestion and post-nasal drip. Azelastine nasal spray is effective at the lower dose of 1 spray as well at a dose of 2 sprays per nostril twice daily, but with an improved tolerability profi le compared to the 2-spray per nostril twice daily regimen. Compared with intranasal corticosteroids, azelastine nasal spray has a faster onset of action and a better safety profile, showing at least comparable efficacy with fluticasone propionate (Flonase®; GSK,USA), and a superior efficacy to mometasone furoate (Nasonex®; Schering Plough, USA). In combination with fluticasone propionate, azelastine nasal spray exhibits greater efficacy than either agent used alone, and this combination may provide benefit for patients with difficult to treat seasonal allergic rhinitis. In addition, azelastine nasal spray can be used on an as-needed basis without compromising clinical efficacy. Compared with oral antihistamines, azelastine nasal spray also demonstrates superior efficacy and a more rapid onset of action, and is effective even in patients who did not respond to previous oral antihistamine therapy. Unlike most oral antihistamines, azelastine nasal spray is effective in alleviating nasal congestion, a particularly bothersome symptom for rhinitis suffers. Azelastine nasal spray is well tolerated in both adults and children with allergic rhinitis. Bitter taste which seems to be associated with incorrect dosing technique is the most common side effect reported by patients, but this problem can be minimized by correct dosing technique.

Keywords: azelastine nasal spray, rhinitis, intranasal corticosteroids, oral antihistamines, seasonal allergic rhinitis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

The influence of bile salt on the chemotherapeutic response of docetaxel-loaded thermosensitive nanomicelles

Kim DW, Ramasamy T, Choi JY, Kim JH, Yong CS, Kim JO, Choi HG

International Journal of Nanomedicine 2014, 9:3815-3824

Published Date: 8 August 2014

Causes and consequences of sleepiness among college students

Hershner SD, Chervin RD

Nature and Science of Sleep 2014, 6:73-84

Published Date: 23 June 2014

Evaluation of glycophenotype in breast cancer by quantum dot-lectin histochemistry

Andrade CG, Cabral Filho PE, Tenorio DPL, Santos BS, Beltrão EIC, Fontes A, Carvalho Jr LB

International Journal of Nanomedicine 2013, 8:4623-4629

Published Date: 2 December 2013

Evaluation of the genotoxicity of cellulose nanofibers

de Lima R, Feitosa LO, Maruyama CR, Barga MA, Yamawaki PC, Vieira IJ, Teixeira EM, Corrêa AC, Mattoso LH, Fraceto LF

International Journal of Nanomedicine 2012, 7:3555-3565

Published Date: 11 July 2012

ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics

Barratt DT, Coller JK, Hallinan R, Byrne A, White JM, Foster DJR, Somogyi AA

Pharmacogenomics and Personalized Medicine 2012, 5:53-62

Published Date: 18 April 2012

Renal and vascular benefits of C-peptide: Molecular mechanisms of C-peptide action

Lina Nordquist, Fredrik Palm, Bradley T Andresen

Biologics: Targets and Therapy 2008, 2:441-452

Published Date: 12 September 2008

Mirtazapine in the treatment of essential tremor: an open-label, observer-blind study

Davide Uccellini, G Grampa, I La Spina, D Nasuelli, I Neromante, L Politini, F Reverberi, D Porazzi, V Carli, G Camardese

Neuropsychiatric Disease and Treatment 2006, 2:95-100

Published Date: 15 March 2006